An evaluation by Bunnell et.al. highlighted the potential adverse consequences of cost-related non-adherence to oral vancomycin therapy and the challenges that clinicians face when prescribe oral vancomycin capsules.
The Information contained herein, including product information, is intended only for residents of the United States.
©2025 Azurity Pharmaceuticals, Inc. All Rights Reserved. All Trademarks referred to are the property of their respective owners.
PP-FKS-US-0119
Notifications
